Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
11(58%)
Results Posted
25%(1 trials)
Terminated
2(11%)

Phase Distribution

Ph early_phase_1
2
11%
Ph phase_2
4
21%
Ph not_applicable
8
42%
Ph phase_1
2
11%

Phase Distribution

4

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution16 total trials
Early Phase 1First-in-human
2(12.5%)
Phase 1Safety & dosage
2(12.5%)
Phase 2Efficacy & side effects
4(25.0%)
N/ANon-phased studies
8(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

11

trials recruiting

Total Trials

19

all time

Status Distribution
Active(11)
Completed(4)
Terminated(4)

Detailed Status

Recruiting6
Active, not recruiting5
Completed4
Terminated2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
19
Active
11
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (12.5%)
Phase 12 (12.5%)
Phase 24 (25.0%)
N/A8 (50.0%)

Trials by Status

terminated211%
active_not_recruiting526%
withdrawn211%
completed421%
recruiting632%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT06454383Phase 1

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Recruiting
NCT05415709Early Phase 1

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Recruiting
NCT06440850Phase 2

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Recruiting
NCT06013423Phase 2

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Recruiting
NCT04539808Phase 2

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Active Not Recruiting
NCT05045027Early Phase 1

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

Active Not Recruiting
NCT05031897Phase 2

Two Step Haplo With Radiation Conditioning

Recruiting
NCT04014231

Novel Single Wave Assessment in Measuring Cardiac Dysfunction and Metabolic Syndrome in Patients With Cancer

Active Not Recruiting
NCT07000266Not Applicable

The RECOVERY Study: Using Supersaturated Oxygen Therapy To Treat Small Vessel Blockages After a Heart Attack

Active Not Recruiting
NCT04535401Phase 1

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Active Not Recruiting
NCT05512767Not Applicable

A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation

Withdrawn
NCT03134586Not Applicable

Advanced Non-Invasive Diagnostics in Inflammatory Bowel Disease

Completed
NCT02742402Not Applicable

DIAgnostic iMaging or Observation in Early Equivocal appeNDicitis

Completed
NCT04477824

Is Acute Appendicitis Still a Clinical Diagnosis?

Completed
NCT03853447

Fibro-inflammatory Progression From Acute to Chronic Pancreatitis

Recruiting
NCT00265902Not Applicable

Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma

Terminated
NCT01767961Not Applicable

Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer

Withdrawn
NCT00971438Not Applicable

Structured Management of Patients With Suspicion of Appendicitis Using a Clinical Score and Selective Imaging

Terminated
NCT00001601Not Applicable

Evaluation and Treatment of Oral Soft Tissue Diseases

Completed

All 19 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
19